Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
This is a double-blind placebo controlled dose escalation trial evaluating efficacy and safety of inactivated rFVIIa (FFR-rFVIIa) as an antithrombotic agent. The trial showed a dose dependent prolongation of the prothrombin time. Future studies in patients undergoing vascular intervention are required. – M. Aldouri. FFR-rFVIIa is a variant activated factor VII molecule that is characterised […]